Management tracks: BioTime, Immune-Onc

Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi Mohanty and Michael West. Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS).

Immunotherapy company Immune-Onc Therapeutics Inc. (Palo Alto, Calif.) hired Adrian Jubb as CMO and An Song as SVP of development sciences. Jubb was VP and head of early development at Achaogen Inc. (NASDAQ:AKAO). Song was senior director in the Genentech Research and Early Development (gRED) division at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)...